ARTICLE | Company News
Dimension Therapeutics, ReGenX deal
November 4, 2013 8:00 AM UTC
ReGenX granted newco Dimension an exclusive, worldwide license to NAV vector technology and rights to undisclosed, preclinical programs in rare disease indications. Dimension will develop adeno-associ...